Insider Selling: ClearPoint Neuro (NASDAQ:CLPT) CEO Sells $45,822.51 in Stock

ClearPoint Neuro, Inc. (NASDAQ:CLPT) CEO Joseph Burnett sold 2,943 shares of the business’s stock in a transaction that occurred on Monday, January 26th. The shares were sold at an average price of $15.57, for a total value of $45,822.51. Following the completion of the sale, the chief executive officer owned 214,116 shares of the company’s stock, valued at $3,333,786.12. This trade represents a 1.36% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Joseph Burnett also recently made the following trade(s):

• On Friday, January 9th, Joseph Burnett sold 20,000 shares of ClearPoint Neuro stock. The stock was sold at an average price of $16.12, for a total value of $322,400.00.

ClearPoint Neuro Price Performance

Shares of NASDAQ:CLPT traded up $0.19 during midday trading on Tuesday, hitting $14.39. The company had a trading volume of 422,044 shares, compared to its average volume of 753,946. ClearPoint Neuro, Inc. has a twelve month low of $9.76 and a twelve month high of $30.10. The stock has a market cap of $408.96 million, a price-to-earnings ratio of -17.13 and a beta of 0.91. The company has a debt-to-equity ratio of 1.84, a current ratio of 6.37 and a quick ratio of 5.56. The business’s 50-day simple moving average is $14.15 and its 200-day simple moving average is $15.22.

ClearPoint Neuro (NASDAQ:CLPT) last posted its earnings results on Thursday, November 6th. The company reported ($0.21) earnings per share for the quarter, missing the consensus estimate of ($0.20) by ($0.01). The firm had revenue of $5.36 million during the quarter, compared to analyst estimates of $9.60 million. ClearPoint Neuro had a negative net margin of 67.40% and a negative return on equity of 114.28%. On average, research analysts predict that ClearPoint Neuro, Inc. will post -0.66 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on CLPT. Wall Street Zen lowered ClearPoint Neuro from a “hold” rating to a “sell” rating in a research report on Saturday, November 15th. Weiss Ratings reiterated a “sell (d-)” rating on shares of ClearPoint Neuro in a report on Wednesday, January 21st. Two analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $14.50.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. Millennium Management LLC increased its position in shares of ClearPoint Neuro by 156.3% in the 1st quarter. Millennium Management LLC now owns 741,193 shares of the company’s stock valued at $8,813,000 after purchasing an additional 452,043 shares during the last quarter. Goldman Sachs Group Inc. lifted its holdings in ClearPoint Neuro by 98.3% during the 1st quarter. Goldman Sachs Group Inc. now owns 257,871 shares of the company’s stock worth $3,066,000 after buying an additional 127,823 shares during the last quarter. Parsons Capital Management Inc. RI lifted its holdings in ClearPoint Neuro by 0.7% during the 2nd quarter. Parsons Capital Management Inc. RI now owns 143,486 shares of the company’s stock worth $1,713,000 after buying an additional 950 shares during the last quarter. MGO One Seven LLC lifted its holdings in shares of ClearPoint Neuro by 9.6% in the 2nd quarter. MGO One Seven LLC now owns 17,949 shares of the company’s stock valued at $214,000 after purchasing an additional 1,569 shares during the last quarter. Finally, AlphaQuest LLC boosted its position in shares of ClearPoint Neuro by 433.5% in the 2nd quarter. AlphaQuest LLC now owns 9,411 shares of the company’s stock valued at $112,000 after purchasing an additional 7,647 shares during the period. Hedge funds and other institutional investors own 30.08% of the company’s stock.

About ClearPoint Neuro

ClearPoint Neuro, Inc is a medical technology company specializing in the development and commercialization of an MRI-guided therapy platform for minimally invasive neurosurgical procedures. Headquartered in Cambridge, Massachusetts, the company’s flagship ClearPoint® SmartFrame™ system enables surgeons to perform accurate and efficient intracranial interventions by providing real-time magnetic resonance imaging feedback. This technology is designed to improve patient safety and outcomes in treatments ranging from deep brain stimulation electrode placement to laser ablation of epileptic foci and brain tumors.

The ClearPoint System integrates hardware, software and imaging capabilities to guide instruments through the brain with submillimeter precision.